Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.41 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.41 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.41 |
| ▸ | ESRRG | P62508 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL582948 | 0.93 | POLB (0.43) | HDAC6RECQLCRBNESRRGHPGD | |
| SCHEMBL582280 | 0.88 | TSHR (0.47) | TSHRHTTHDAC6SMN1; SMN2RECQL | |
| SCHEMBL29644326 | 0.81 | GAA (0.44) | HTTSMN1; SMN2HDAC1 | |
| SCHEMBL2411518 | 0.81 | GAA (0.44) | HTTSMN1; SMN2HDAC1 | |
| SCHEMBL582255 | 0.81 | POLB (0.44) | HDAC6RECQLCRBNESRRGHPGD | |
| SCHEMBL582706 | 0.80 | POLB (0.44) | HTTSMN1; SMN2HDAC1 | |
| SCHEMBL24965982 | 0.79 | EPHX2 (0.41) | — | |
| SCHEMBL29563554 | 0.79 | KDM4E (0.40) | SMN1; SMN2HPGDCA12CA1CA2 | |
| SCHEMBL10020940 | 0.79 | MAOB (0.39) | HDAC1 | |
| SCHEMBL17658331 | 0.79 | KDM4E (0.40) | SMN1; SMN2HPGDCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8710086-B2 | Substituted di-arylhydantoin and di-arylthiohydantoin compounds and methods of use thereof | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-20120184580-A1 | SUBSTITUTED DI-ARYLHYDANTOIN AND DI-ARYLTHIOHYDANTOIN COMPOUNDS AND METHODS OF USE THEREOF | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184580-A1 | SUBSTITUTED DI-ARYLHYDANTOIN AND DI-ARYLTHIOHYDANTOIN COMPOUNDS AND METHODS OF USE THEREOF | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184580-A1 | SUBSTITUTED DI-ARYLHYDANTOIN AND DI-ARYLTHIOHYDANTOIN COMPOUNDS AND METHODS OF USE THEREOF | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| EP-2416657-A1 | SUBSTITUTED DI-ARYLHYDANTOIN AND DI-ARYLTHIOHYDANTOIN COMPOUNDS AND METHODS FOR USE THEREOF | Medivation Prostate Therapeutics, Inc. (US) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010118354-A1 | SUBSTITUTED DI-ARYLHYDANTOIN AND DI-ARYLTHIOHYDANTOIN COMPOUNDS AND METHODS FOR USE THEREOF | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010118354-A1 | SUBSTITUTED DI-ARYLHYDANTOIN AND DI-ARYLTHIOHYDANTOIN COMPOUNDS AND METHODS FOR USE THEREOF | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184580-A1 | SUBSTITUTED DI-ARYLHYDANTOIN AND DI-ARYLTHIOHYDANTOIN COMPOUNDS AND METHODS OF USE THEREOF | AR, BRDT, AADAC | TSHR 949/4885HTT 1889/4885HDAC6 1206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.